Loading of MHC Class I and II Presentation Pathways by Exogenous Antigens: A Quantitative In Vivo Comparison

The MHC class I pathway is usually fueled by endogenous Ags, while exogenous Ags reach the MHC class II pathway. Although exogenous epitopes may also enter the MHC class I pathway, quantification of the efficiency of the process has remained a difficult task. In an attempt of such a quantification, we directly compared the amount of exogenous virus-like particles required for induction of cytotoxic T cell responses by cross-priming with the amount of virus-like particles required for induction of Th cell responses by the conventional route of MHC class II loading as an internal standard. Surprisingly, we found that cross-presentation of peptides derived from exogenous Ags on MHC class I molecules is of only marginally lower efficiency (∼1- to 10-fold) than the classical MHC class II pathway in vitro and in vivo. Thus, Ag quantities required for cross-presentation and cross-priming are similar to those required for fueling the MHC class II pathway.

[1]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[2]  C. Harding,et al.  Processing of Exogenous Antigens for Presentation by Class I MHC Molecules Involves Post-Golgi Peptide Exchange Influenced by Peptide-MHC Complex Stability and Acidic pH , 2003, The Journal of Immunology.

[3]  Peter J. S. Hutzler,et al.  Tumor-Derived Heat Shock Protein 70 Peptide Complexes Are Cross-Presented by Human Dendritic Cells1 , 2002, The Journal of Immunology.

[4]  G. Lipowsky,et al.  Regulation of IgG antibody responses by epitope density and CD21‐mediated costimulation , 2002, European journal of immunology.

[5]  R. Zinkernagel On cross‐priming of MHC class I‐specific CTL: rule or exception? , 2002, European journal of immunology.

[6]  U. Koszinowski,et al.  The Murine Cytomegalovirus Immunomodulatory Gene m152 Prevents Recognition of Infected Cells by M45-Specific CTL But Does Not Alter the Immunodominance of the M45-Specific CD8 T Cell Response In Vivo1 , 2002, The Journal of Immunology.

[7]  J. Yewdell,et al.  Inhibitory Effects of Cytomegalovirus Proteins US2 and US11 Point to Contributions from Direct Priming and Cross-Priming in Induction of Vaccinia Virus-Specific CD8+ T Cells , 2002, The Journal of Immunology.

[8]  A. Jegerlehner,et al.  Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles1 , 2002, The Journal of Immunology.

[9]  Scott N. Mueller,et al.  Rapid Cytotoxic T Lymphocyte Activation Occurs in the Draining Lymph Nodes After Cutaneous Herpes Simplex Virus Infection as a Result of Early Antigen Presentation and Not the Presence of Virus , 2002, The Journal of experimental medicine.

[10]  F. Lechner,et al.  Cross‐presentation of virus‐like particles by skin‐derived CD8– dendritic cells: a dispensable role for TAP , 2002, European journal of immunology.

[11]  J. Yewdell,et al.  Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo , 2002, Nature Immunology.

[12]  Antonio Lanzavecchia,et al.  Regulation of T Cell Immunity by Dendritic Cells , 2001, Cell.

[13]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[14]  P. Pumpens,et al.  HBV Core Particles as a Carrier for B Cell/T Cell Epitopes , 2001, Intervirology.

[15]  J. Yewdell,et al.  Cutting Edge: Recombinant Adenoviruses Induce CD8 T Cell Responses to an Inserted Protein Whose Expression Is Limited to Nonimmune Cells , 2001, The Journal of Immunology.

[16]  J. Lifson,et al.  MHC-I–restricted presentation of HIV-1 virion antigens without viral replication , 2001, Nature Medicine.

[17]  R. Steinman,et al.  Brief Definitive Report Dendritic Cells Cross-present Latency Gene Products from Epstein-barr Virus–transformed B Cells and Expand Tumor-reactive Cd8 Ϩ Killer T Cells , 2022 .

[18]  M. Bevan,et al.  Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo , 2000, The Journal of experimental medicine.

[19]  P. Loetscher,et al.  Cxc Chemokine Receptor 5 Expression Defines Follicular Homing T Cells with B Cell Helper Function , 2000, The Journal of experimental medicine.

[20]  H. Rammensee,et al.  Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis , 2000, The Journal of experimental medicine.

[21]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[22]  N. Shastri,et al.  Bacterial Proteins Can Be Processed by Macrophages in a Transporter Associated with Antigen Processing-Independent, Cysteine Protease-Dependent Manner for Presentation by MHC Class I Molecules1 , 2000, The Journal of Immunology.

[23]  J. Yewdell,et al.  Generating MHC class I ligands from viral gene products , 1999, Immunological reviews.

[24]  J. Neefjes,et al.  Recycling MHC class I molecules and endosomal peptide loading. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[26]  R. Zinkernagel,et al.  Virus‐specific major MHC class II‐restricted TCR‐transgenic mice: effects on humoral and cellular immune responses after viral infection , 1998, European journal of immunology.

[27]  A. Diehl,et al.  TAP peptide transporter-independent presentation of heat-killed Sendai virus antigen on MHC class I molecules by splenic antigen-presenting cells. , 1997, Journal of immunology.

[28]  F. Marincola,et al.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Hans Hengartner,et al.  Antigen localisation regulates immune responses in a dose‐ and time‐dependent fashion: a geographical view of immune reactivity , 1997, Immunological reviews.

[30]  J. Pfeifer,et al.  Major histocompatibility complex class I presentation of ovalbumin peptide 257–264 from exogenous sources: protein context influences the degree of TAP‐independent presentation , 1996, European journal of immunology.

[31]  D. Pardoll,et al.  In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. , 1996, Immunity.

[32]  H. Rammensee,et al.  Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96 , 1995, The Journal of experimental medicine.

[33]  S. Tonegawa,et al.  TAP1‐independent loading of class I molecules by exogenous viral proteins , 1995, European journal of immunology.

[34]  J. Reimann,et al.  Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I‐restricted epitope presentation , 1995, European journal of immunology.

[35]  M. Kovacsovics-Bankowski,et al.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules , 1995, Science.

[36]  R. Zinkernagel,et al.  Induction of protective cytotoxic T cells with viral proteins , 1994, European journal of immunology.

[37]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[38]  Hans Hengartner,et al.  Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice , 1994, Nature.

[39]  R. Zinkernagel,et al.  Immunogenicity of a viral model vaccine after different inactivation procedures , 1994, Medical Microbiology and Immunology.

[40]  T. Kündig,et al.  In vivo versus in vitro assays for assessment of T- and B- cell function. , 1994, Current opinion in immunology.

[41]  J. Reimann,et al.  Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. , 1994, Journal of immunology.

[42]  K. Rock,et al.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Pfeifer,et al.  Phagocytic processing of bacterial antigens for class I MHC presentation to T cells , 1993, Nature.

[44]  R M Zinkernagel,et al.  Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. , 1991, Journal of virological methods.

[45]  H. Pircher,et al.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen , 1989, Nature.

[46]  M. Gething,et al.  Antigen Presentation Pathways to Class I and Class II MHC‐Restricted T Lymphocytes , 1987, Immunological reviews.

[47]  R. Zinkernagel,et al.  Effects of cyclosporin A on humoral immune response and resistance against vesicular stomatitis virus in mice , 1986, Journal of virology.

[48]  J. Schulman,et al.  Cellular immune responses of mice to influenza virus vaccines. , 1980, Journal of immunology.

[49]  J. Oliver,et al.  Topographical distribution of coated pits , 1980, Nature.

[50]  T. Braciale,et al.  Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells , 1978, The Journal of experimental medicine.

[51]  M. Bevan,et al.  Induction of H-2-restricted cytotoxic T cells: in vivo induction has the appearance of being unrestricted. , 1977, Cellular immunology.

[52]  M. Bevan,et al.  Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. , 1976, Journal of immunology.

[53]  R. Germain,et al.  The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. , 1999, Annual review of immunology.

[54]  R. Andino,et al.  Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen , 1999, Nature.

[55]  R. Zinkernagel,et al.  Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. , 1996, Annual review of immunology.

[56]  H. Ploegh,et al.  Generation, translocation, and presentation of MHC class I-restricted peptides. , 1995, Annual review of biochemistry.

[57]  M. Battegay [Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24 well plates] , 1993, ALTEX.

[58]  M. Bevan,et al.  Class I MHC-restricted cytotoxic responses to soluble protein antigen. , 1989, Cold Spring Harbor symposia on quantitative biology.